Please assess the completion status of the following clinical trial:

Trial Title: Drug to Drug Interaction Study With ASP1941 and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* Stable disease under metformin monotherapy (between 1500-3000~mg/day) or dual therapy with metformin (1500-3000 mg/day) and a Sulfonylureum Derivative (SUD) for at least 3 months~* Fasting Serum Glucose: 7-11.5 mmol/l (after wash-out)~* Stable Fasting Blood Glucose (FBG) at the end of wash-out~* BMI between 18.5 and 40.0 kg/m2, inclusive~Exclusion Criteria:~* Subjects with type 1 diabetes~* Any diabetes related macro-complications, painful diabetic neuropathy, diabetic macular edema or diabetic proliferative retinopathy~* Clinical significant renal disease (CLcr \<60 ml/min as assessed during a 24h creatinine clearance on Day-2~* Recent evidence (e.g. within the last 6 months) of severe hypoglycemia, for example plasma glucose \<3 mmol/l (\<55 mg/dl) or requiring hospitalization~* Pulse \<40 or \>90; Systolic Blood Pressure \>160 mmHg; Diastolic Blood Pressure \> 100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASP1941 + metformin (Type: EXPERIMENTAL): Oral
- Placebo + metformin (Type: PLACEBO_COMPARATOR): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).